A method for the measurement of methotrexate based on its inhibition of dihydrofolate reductase (EC 1.5.1.3) is described. The performance of the method is evaluated and a brief assessment of its clinical usefulness made.
Reaction time, pH, and the relative concentration of enzyme and inhibitor all have a significant effect on the shape of the standard curve. Pre-incubation of enzyme with methotrexate resulted in increased inhibition, but did not improve the sensitivity or linearity of the assay. Data are presented on the imprecision, specificity and accuracy of the method. The method is simple to perform, rapid and inexpensive.
The sensitivity and specificity of the method are such as to allow for effective monitoring of patients on methotrexate therapy.
References
1.
Von HoffDDPentaJSHelmanLJSlavikM. Incidence of drug related deaths secondary to high-dose methotrexate and citrovorum factor administration. Cancer Treat Rep1977; 61: 745–8.
2.
JacobsSAStollerRGChabnerBAJohnsDG. 7-hydroxymethotrexate as a urinary metabolite in human subjects and rhesus monkeys receiving high-dose methotrexate. J Clin Invest1976; 57: 534–8.
3.
Freeman-NarrodMFKimSJOhanissianHThe effect of high-dose methotrexate on renal tubules as indicated by urinary lysozyme concentration. Cancer1982; 50: 2775–9.
4.
EvansNEPrattCB. Effect of pleural effusion on high-dose methotrexate kinetics. Clin Pharmacol Ther1978; 23: 68–72.
5.
EvansWETsiatisACromWRPharmacokinetic simulation of gastrointestinal obstruction as a mechanism for delayed clearance of high-dose methotrexate in children. Clin Res1980; 28: 588 (abstract).
6.
StollerRGHanderKRJacobsSAChabnerBA. Use of plasma pharmacokinetics to predict and prevent methotrexate toxicity. N Engl J Med1977; 297: 630–4.
7.
NirenbergAMosendeCMehtaBMHigh-dose methotrexate with C F rescue: Predictive value of serum methotrexate concentrations and corrective measures to avert toxicity. Cancer Treat Rep1977; 61: 779–83.
8.
EvansWEPrattCBTaylorRHPharmacokinetic monitoring of high-dose methotrexate: early recognition of high-risk patients. Cancer Chemother Pharmacol1979; 3: 161–6.
9.
FalkLCClarkDRSumnerMKLongTF. Enzymatic assay for methotrexate in serum and cerebrospinal fluid. Clin Chem1976; 22(6): 785–8.
10.
FinleyPRWilliamsRS. Methotrexate assay by enzymatic inhibition, with use of a centrifugal analyser. Clin Chem1977; 23(11): 2139–41.
11.
BrooksRJ. Use of dihydrofolate reductase from bovine liver, rather than from L. caesii, for determining methotrexate. Clin Chem1978; 24(3): 518–9.
12.
BrowneLFJohnsonGFWitteDLFeldRD. Enzymic inhibition assay for methotrexate with a discrete analyser, the ABA-100. Clin Chem1980; 26(2): 335–8.
13.
PesceMABodourianSH. Enzyme immunoassay and enzyme inhibition assay of methotrexate, with use of a centrifugal analyser. Clin Chem1981; 27(3): 380–4.
14.
ScheuflerE. Improved enzymatic assay for methotrexate; shape of standard curve, stability of reagents, sensitivity. Clin Chim Acta1981; 111: 113–6.
15.
ImbertAMPignonTLenaN.Enzymatic assay for methotrexate with a centrifugal analyser (Cobas-Bio). Clin Chem1983; 29(6): 1317–8.
16.
EdwardsMFishRG. Dihydrofolate reductase inhibition assay for methotrexate. Ann Clin Biochem1985; 22: 612–3.
17.
FinleyPRWilliamsRJGriffithFLichtzDA. Adaptation of the enzyme-multiplied immunoassay for methotrexate to the centrifugal analyser. Clin Chem1980; 26(2): 341–3.
18.
WilliamsMNPocMGreenfieldNJ. Methotrexate binding to dihydrofolate reductase from a methotrexate resistant strain of. E. coliJ Biol Chem1973; 248: 6375.
19.
WilmannsW.In: Bergmeyer HW, edMethods of Enzymatic Analysis. New York: Academic Press, 1974; 2: 666.
20.
HigniteCEShenDDAzarnoffDL. Separation and identification of impurities in parenteral methotrexate dosage forms. Cancer Treat Rep1978; 62: 13–18.
21.
BockJLPierceR.Trimethoprim interference in methotrexate assays. Clin Chem1980; 26(10): 1510–11.
